Theriva Biologics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2023-12-31 was 0.00 shares.
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2023-09-30 was 0.00 shares.
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2022-03-31 was 0.00 shares.
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2013-09-30 was 0.00 shares.
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 0.00 shares.
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 0.00 shares.
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 0.00 shares.
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2017 was 11.96K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | 0.00 shares 10-K · filed 2024-03-25 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | |
| 2022-12-31 | 0.00 shares 10-K · filed 2023-03-30 | |
| 2022-03-31 | 0.00 shares 10-Q · filed 2023-05-11 | |
| 2021-12-31 | 0.00 shares 10-K · filed 2022-03-16 | |
| 2017-12-31 | 11.96K shares 10-K · filed 2019-02-27 | |
| 2013-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-14 | 1.00M shares derived: sum of 4 quarters · filed 2013-11-14 |
| 2013-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-14 | 1.00M shares derived: sum of 4 quarters · filed 2013-11-14 |
| 2013-03-31 | 291.67K shares 10-Q · filed 2013-05-15 | |
| 2012-12-31 | 709.70K shares derived: 10-Q 12 month − 10-Q 9 month · filed 2013-11-14 | 374.85K shares 10-Q · filed 2013-11-14 |
| 2012-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q/A 6 month · filed 2012-11-14 | |
| 2011-12-31 | 33.33K shares derived: 10-K 12 month − 10-Q 9 month · filed 2013-04-16 | 23.33K shares 10-K · filed 2013-04-16 |
| 2011-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q/A 6 month · filed 2012-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |